Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Vanda Pharmaceuticals, Inc.

      Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Vanda
                            Pharmaceuticals, Inc.

PR Newswire

WAYNE, Pa., June 28, 2013

WAYNE, Pa., June 28, 2013 /PRNewswire/ --Ryan & Maniskas, LLP
(www.rmclasslaw.com/cases/vnda) announces that a class action lawsuit has been
filed in the United States District Court for the District of Columbia on
behalf of purchasers of Vanda Pharmaceuticals, Inc. ("Vanda" or the "Company")
(NASDAQ: VNDA) between December 18, 2012 and June 18, 2013, inclusive (the
"Class Period").

(Logo: http://photos.prnewswire.com/prnh/20121112/MM11729LOGO )

For more information regarding this class action suit, please contact Ryan &
Maniskas, LLP (Richard A. Maniskas, Esquire) toll-free at (877) 316-3218 or by
email at rmaniskas@rmclasslaw.com or visit: www.rmclasslaw.com/cases/vnda.

Vanda is a biopharmaceutical company engaged in the development and
commercialization of products for the treatment of central nervous system
disorders, including tasimelteon -- a treatment for circadian rhythm sleep
disorders ("CRSD") and currently in clinical development for a serious, rare
CRSD known as "Non-24." The Complaint alleges that during the Class Period the
Company issued false and/or misleading statements and/or failed to disclose
the following: (1) the Company was forced to unilaterally change the primary
endpoint in the middle of the tasimelteon Phase III studies as it was in
possession of data suggesting the original primary endpoint would not be met;
(2) the Company eliminated nighttime total sleep as the primary endpoint in
its studies as there was no discernible difference in efficacy and safety in
nighttime total sleep between those patients deemed to have Non-24 and those
patients with a normal circadian rhythm; (3) the replacement primary endpoint
installed to assess tasimelteon's efficacy and safety was created by the
Company based on predicted results and has never been used before in
sleep-drug clinical trials, nor was it endorsed by the Food and Drug
Administration; and (4) as a result of the foregoing, the Company's statements
were materially false and misleading at all relevant times.

On June 19, 2013, The Street published an article raising doubts about the
quality and efficacy of Vanda's clinical trial procedure and test data. Among
other issues, the article noted multiple changes in the primary endpoint over
the course of the trials, including a change just one month before study
results were published to a new primary endpoint that has allegedly never been
used before in sleep-drug clinical trials, nor was it endorsed by the FDA. The
article also states that Vanda was forced to cut patient enrollment in the
clinical trials in half because an insufficient number of totally blind
patients with Non-24 could not be identified, and that ultimately less than 5%
of the patients enrolled in the trials suffered from Non-24 according to the
"textbook definition" of the disease. On this news, Vanda shares declined
$2.41 per share or more than 22%, to close at $8.51 per share on June 19,

If you are a member of the class, you may, no later than August 24, 2013,
request that the Court appoint you as lead plaintiff of the class. A lead
plaintiff is a representative party that acts on behalf of other class members
in directing the litigation. In order to be appointed lead plaintiff, the
Court must determine that the class member's claim is typical of the claims of
other class members, and that the class member will adequately represent the
class. Under certain circumstances, one or more class members may together
serve as "lead plaintiff." Your ability to share in any recovery is not,
however, affected by the decision whether or not to serve as a lead plaintiff.
You may retain Ryan & Maniskas, LLP or other counsel of your choice, to serve
as your counsel in this action.

For more information about the case or to participate online, please visit:
www.rmclasslaw.com/cases/vnda or contact Richard A. Maniskas, Esquire
toll-free at (877) 316-3218, or by e-mail at rmaniskas@rmclasslaw.com. For
more information about class action cases in general or to learn more about
Ryan & Maniskas, LLP, please visit our website: www.rmclasslaw.com.

Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan &
Maniskas, LLP is devoted to protecting the interests of individual and
institutional investors in shareholder actions in state and federal courts

Ryan & Maniskas, LLP
Richard A. Maniskas, Esquire
995 Old Eagle School Rd., Suite 311
Wayne, PA 19087

SOURCE Ryan & Maniskas, LLP

Website: http://www.rmclasslaw.com
Press spacebar to pause and continue. Press esc to stop.